According to recent Phase 2 study data reported by Windtree Therapeutics, Aerosurf (lucinactant for inhalation) administered noninvasively via nasal continuous positive airway pressure (nCPAP) in premature infants 29-34 weeks gestational age (GA) with respiratory distress syndrome (RDS) was generally safe and well tolerated and may be reducing the incidence of nCPAP failure (the need for invasive intubation and delayed surfactant therapy). The data was presented in an abstract at the 6th International Congress of European Neonatal and Perinatal Societies in Valencia Spain, where the abstract received the UENPS Congress 2016 Best Abstract Award.
Aerosurf (lucinactant for inhalation) is a novel, investigational combination drug/device product that combines the Windtree’s proprietary KL4 surfactant and aerosolization technologies. Aerosurf is being developed to potentially reduce or eliminate the need for endotracheal intubation and mechanical ventilation in the treatment of premature infants with RDS.
“We are very pleased with the safety and tolerability seen with Aerosurf in the phase 2 program thus far and are encouraged by the reduction of nCPAP failures seen when using Aerosurf in preterm neonates 29-34 weeks GA,” stated Steve Simonson, MD, Senior Vice President and Chief Development Officer. “Though further study is required, if we are successful, we believe Aerosurf will represent a transformational change in the management of RDS. We are very pleased that UENPS acknowledged this work with the Best Abstract Award at its Congress. We believe this award recognizes the importance to the neonatal community of pursuing a non-invasive treatment for RDS and acknowledges the quality of the study and the potential of Aerosurf.”